Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

被引：0
|
作者：
E. Claire Dees
Jeffrey R. Infante
Roger B. Cohen
Bert H. O’Neil
Suzanne Jones
Margaret von Mehren
Hadi Danaee
Yih Lee
Jeffrey Ecsedy
Mark Manfredi
Katherine Galvin
Bradley Stringer
Hua Liu
Omar Eton
Howard Fingert
Howard Burris
机构：
[1] University of North Carolina,UNC Lineberger Comprehensive Cancer Center
[2] Sarah Cannon Research Institute,undefined
[3] Fox Chase Cancer Center,undefined
[4] Millennium Pharmaceuticals,undefined
[5] Inc.,undefined
[6] Forest Research Institute,undefined
[7] Inc.,undefined
[8] Boston University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
MLN8054; Aurora A kinase; Dose-limiting toxicity; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：945 / 954
页数：9
相关论文
共 50 条
  • [41] Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors
    Falchook, Gerald S.
    Venkatakrishnan, Karthik
    Sarantopoulos, John
    Kurzrock, Razelle
    Mita, Alain C.
    Fu, Siqing
    Mita, Monica M.
    Zhou, Xiaofei
    Jung, Jung Ah
    Ullmann, Claudio Dansky
    Milch, Catherine
    Rosen, Lee S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 563 - 572
  • [42] Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies
    Padmanabhan, Swaminathan
    Shea, Thomas C.
    Vose, Julie M.
    Reeder, Craig B.
    Berdeja, Jesus G.
    McDonagh, Kevin T.
    Goy, Andre
    Kelly, Kevin R.
    Zhou, Xiaofei
    Liu, Hua
    Fingert, Howard
    Fowler, Nathan
    BLOOD, 2010, 116 (21) : 1154 - 1154
  • [43] Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
    Dees, E. Claire
    Cohen, Roger B.
    von Mehren, Margaret
    Stinchcombe, Thomas E.
    Liu, Hua
    Venkatakrishnan, Karthik
    Manfredi, Mark
    Fingert, Howard
    Burris, Howard A., III
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4775 - 4784
  • [44] A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
    Olszanski, Anthony J.
    Middleton, Mark R.
    Bahleda, Rastilav
    Heist, Rebecca Suk
    Rangachari, Lakshmi
    Zhou, Xiaofei
    Bozon, Viviana
    Kneissl, Michelle
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] A phase Ib study of the combination of alisertib (Aurora A kinase inhibitor) and MLN0128 (dual TORC1/2 Inhibitor) in patients with advanced solid tumors, final expansion cohort data.
    Davis, S. Lindsey
    Leal, Alexis Diane
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    Lam, Elaine T.
    Corr, Bradley
    O'Bryant, Cindy L.
    Serkova, Natalie Julie
    Pitts, Todd
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors, expansion cohort data
    Davis, S. L.
    Leong, S.
    Messersmith, W.
    Purcell, T.
    Lam, E.
    Corr, B.
    Leal, A.
    O'bryant, C.
    Glode, A.
    Adler, N.
    Serkova, N.
    Diamond, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E142 - E142
  • [47] The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomas
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T.
    Lockhart, A.
    Patel, M.
    Zhang, B.
    Kelly, V.
    Ullmann, C. D.
    Bargfrede, M.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 21 - 22
  • [48] MLN8054, an Aurora A kinase inhibitor, inhibits proliferation of cultured human tumor cells by p53-dependent and p53-independent mechanisms.
    LeRoy, PJ
    Wysong, DR
    Hoar, KM
    Ecsedy, JA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9108S - 9108S
  • [49] A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors
    Kristeleit, R.
    Calvert, H.
    Arkenau, H.
    Olmos, D.
    Adam, J.
    Plummer, E. R.
    Lock, V.
    Squires, M.
    Fazal, L.
    Judson, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
    Quincy Siu-chung Chu
    Nathaniel Bouganim
    Caroline Fortier
    Sara Zaknoen
    John R. Stille
    Jill D. Kremer
    Eunice Yuen
    Yu-Hua Hui
    Amparo de la Peña
    Andrew Lithio
    Patricia S. Smith
    Gerald Batist
    Investigational New Drugs, 2021, 39 : 1001 - 1010
12345